These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39146874)

  • 1. Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors.
    Adhikari A; Sapkota S; Gogia S; Kc O
    Cancer Epidemiol; 2024 Oct; 92():102639. PubMed ID: 39146874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the survival of adult patients with metastasized melanoma with the approval of immune checkpoint inhibitors: A retrospective study from the United States database.
    Adhikari A; Cha E; Antala D; Sapkota S; Bhattarai U
    Cancer Epidemiol; 2022 Dec; 81():102254. PubMed ID: 36162155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
    Choueiri TK; Albiges L; Barthélémy P; Iacovelli R; Emambux S; Molina-Cerrillo J; Garmezy B; Barata P; Basu A; Bourlon MT; Moon H; Ratta R; McKay RR; Chehrazi-Raffle A; Hammers H; Heng DYC; Braendle E; Beckermann KE; McGregor BA; Motzer RJ
    Lancet; 2024 Oct; 404(10460):1309-1320. PubMed ID: 39284329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(5):793-801. PubMed ID: 33324983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
    Pignot G; Thiery-Vuillemin A; Albigès L; Walz J; Lang H; Balssa L; Parier B; Geoffrois L; Bensalah K; Schlürmann F; Ladoire S; Bigot P; Borchiellini D; Cassuto O; Thibault C; Ingels A; Saldana V; Roubaud G; Bernhard JC; Gravis G; Barthélémy P
    Eur Urol Oncol; 2022 Oct; 5(5):577-584. PubMed ID: 35853818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific Response to Nivolumab in Renal Cell Carcinoma.
    Negishi T; Furubayashi N; Nakagawa T; Nishiyama N; Kitamura H; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Okajima E; Nakamura M
    Anticancer Res; 2021 Mar; 41(3):1539-1545. PubMed ID: 33788747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
    Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
    J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial and Ethnic Disparities in Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy.
    Gupta A; Roy AM
    Clin Genitourin Cancer; 2024 Aug; 22(4):102104. PubMed ID: 38834500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.
    Catalano M; Rebuzzi SE; Maruzzo M; De Giorgi U; Buti S; Galli L; Fornarini G; Zucali PA; Claps M; Chiellino S; Zampiva I; Pipitone S; Ricotta R; Sorarù M; Mollica V; Tudini M; Fratino L; Prati V; Caffo O; Atzori F; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Di Napoli M; Malgeri A; Naglieri E; Signori A; Banna GL; Rescigno P; Cerbone L; Antonuzzo L; Roviello G
    Front Immunol; 2024; 15():1361010. PubMed ID: 39034992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors.
    Silberg M; Krabbe LM; Bögemann M; Schrader AJ; Tully K; Schlack K
    Clin Genitourin Cancer; 2024 Oct; 22(5):102164. PubMed ID: 39153900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
    Derosa L; Hellmann MD; Spaziano M; Halpenny D; Fidelle M; Rizvi H; Long N; Plodkowski AJ; Arbour KC; Chaft JE; Rouche JA; Zitvogel L; Zalcman G; Albiges L; Escudier B; Routy B
    Ann Oncol; 2018 Jun; 29(6):1437-1444. PubMed ID: 29617710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
    Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
    Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs).
    Alradhi M; Zhang Z; Safi M; Al-Danakh A; Aldhbi M; Baldi S; Kui L; Alradhi A; Hamri SB; Lun Lo K; Zhao Y; Jin Y
    Front Pharmacol; 2022; 13():996404. PubMed ID: 36686665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
    Carril-Ajuria L; Lavaud P; Dalban C; Negrier S; Gravis G; Motzer RJ; Chevreau C; Tannir NM; Oudard S; McDermott DF; Laguerre B; Hammers HJ; Barthelemy P; Plimack ER; Borchiellini D; Gross-Goupil M; Jiang R; Lee CW; de Silva H; Rini BI; Escudier B; Albigès L
    Eur J Cancer; 2024 Jun; 204():114048. PubMed ID: 38653033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
    Saad E; Gebrael G; Semaan K; Eid M; Saliby RM; Labaki C; Sayegh N; Wells JC; Takemura K; Ernst MS; Lemelin A; Basappa NS; Wood LA; Powles T; Ernst DS; Lalani AA; Agarwal N; Xie W; Heng DYC; Choueiri TK
    Oncologist; 2024 Aug; 29(8):699-706. PubMed ID: 38630540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
    Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
    Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.